(Reuters) -Deciphera Pharmaceuticals said on Monday Japan's Ono Pharmaceutical Co will acquire the cancer drugmaker for $2.4 billion to expand its oncology portfolio and presence in the United States ...

More than three years after Deciphera Pharmaceuticals’ first approval, the company appears to be on the precipice of achieving a second commercial product. Oral tumor treatment vimseltinib passed the ...

OSAKA, Japan & WALTHAM, Mass., November 17, 2025--(BUSINESS WIRE)--Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; "Ono ...

Ono Pharmaceutical is expanding its scope in oncology with a $2.4 billion deal to buy Deciphera Pharmaceutical, a company that has one commercialized cancer therapy and a drug pipeline that includes a ...

Deciphera Pharmaceuticals, Inc. DCPH announced that it has dosed the first patient in a phase I study which is evaluating its investigational ULK kinase inhibitor, DCC-3116, for the treatment of ...

In less than 24 hours, the FDA handed out one rejection and one thumbs-up to two rival drugs for a rare stomach cancer. On the heels of turning down Blueprint Medicines’ Ayvakit as a therapy for ...

Deciphera Pharmaceuticals has filed for FDA approval of ripretinib in patients with advanced gastrointestinal stromal tumors (GISTs). The filing moves Deciphera closer to establishing ripretinib as an ...

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its first quarter 2021 financial results on Tuesday, May 4, 2021. In connection with ...

Deciphera Pharmaceuticals is stopping work on two programs, focusing its research efforts on two others, and cutting its headcount by 35% in a corporate restructuring. The moves announced Tuesday come ...

Deciphera Pharmaceuticals, Inc. DCPH announced an outlook and planned corporate milestones for 2023. The company outlined certain commercial, clinical and preclinical activities for the year. Along ...